LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 3 von insgesamt 3

Suchoptionen

  1. Artikel ; Online: Cognitive modeling and multi criteria decision making in macroeconomic analysis

    Leonova Nina

    Megatrend Revija, Vol 11, Iss 3, Pp 155-

    2014  Band 166

    Abstract: Decision making in macroeconomics belongs to the class of ill-structured tasks with strong external factors interdependence, a limited number of management tools and experts groups' subjectivity. This paper suggests a technique of macroeconomic analysis ... ...

    Abstract Decision making in macroeconomics belongs to the class of ill-structured tasks with strong external factors interdependence, a limited number of management tools and experts groups' subjectivity. This paper suggests a technique of macroeconomic analysis which includes methods of cognitive modeling for formalizing a problem situation and scenario generation as a basis of the typical multicriteria decision making task. In turn, for solving this task is suggested a method based on measuring the distance to the 'ideal' solution with determining importance of criteria by finding objective, common component of all values measured by experts groups. For extracting this 'commonality' means of factor analysis are used. Such an approach allows separating of the objective part in experts' value from a subjective one, while the technique at whole provides formalization of macroeconomic problems and substantiation of decision-making in macroeconomics.
    Schlagwörter cognitive modeling ; combined strategies ; decision making ; ill-structured problems ; macroeconomic analysis ; method of finding generality ; multicriteriality ; Economics as a science ; HB71-74
    Thema/Rubrik (Code) 006
    Sprache Englisch
    Erscheinungsdatum 2014-01-01T00:00:00Z
    Verlag University Dzon Nezbit
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Volltext online

    Zusatzmaterialien

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  2. Artikel: Cognitive modeling and multi criteria decision making in macroeconomic analysis

    Leonova, Nina

    Megatrend revija Vol. 11, No. 3 , p. 155-166

    2014  Band 11, Heft 3, Seite(n) 155–166

    Verfasserangabe Nina Leonova
    Schlagwörter cognitive modeling ; combined strategies ; decision making ; ill-structured problems ; macroeconomic analysis ; method of finding generality ; multicriteriality
    Sprache Englisch
    Erscheinungsort Beograd
    Dokumenttyp Artikel
    Anmerkung Zsfassung in serb. Sprache
    ZDB-ID 27100674321-0
    ISSN 1820-3159
    Datenquelle ECONomics Information System

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  3. Artikel ; Online: Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial.

    Fleseriu, Maria / Dreval, Alexander / Bondar, Irina / Vagapova, Gulnar / Macut, Djuro / Pokramovich, Yulia G / Molitch, Mark E / Leonova, Nina / Raverot, Gerald / Grineva, Elena / Poteshkin, Yury E / Gilgun-Sherki, Yossi / Ludlam, William H / Patou, Gary / Haviv, Asi / Gordon, Murray B / Biermasz, Nienke R / Melmed, Shlomo / Strasburger, Christian J

    The lancet. Diabetes & endocrinology

    2021  Band 10, Heft 2, Seite(n) 102–111

    Abstract: Background: Despite biochemically responding to injectable somatostatin receptor ligands (iSRLs), many patients with acromegaly experience treatment burdens. We aimed to assess maintenance of biochemical response and symptomatic control with oral ... ...

    Abstract Background: Despite biochemically responding to injectable somatostatin receptor ligands (iSRLs), many patients with acromegaly experience treatment burdens. We aimed to assess maintenance of biochemical response and symptomatic control with oral octreotide capsules versus iSRLs in patients with acromegaly who previously tolerated and responded to both.
    Methods: This global, open-label, randomised controlled phase 3 trial was done in 29 clinical sites in Austria, France, Germany, Hungary, Italy, Lithuania, Russia, Serbia, Spain, and the USA. Eligible patients were adults aged 18-75 years with acromegaly who were receiving iSRLs (long-acting octreotide or lanreotide autogel) for at least 6 months before baseline with a stable dose for at least 4 months, and were deemed to be biochemically responding (insulin-like growth factor I [IGF-I] <1·3 × upper limit of normal [ULN] and mean integrated growth hormone <2·5 ng/mL). In the 26-week run-in phase, all patients received oral octreotide (40 mg a day, optional titration to 60 or 80 mg a day). Eligibility for the randomised treatment phase was completion of the run-in phase as a biochemical responder (IGF-I <1·3 × ULN and mean integrated growth hormone <2·5 ng/mL at week 24) and investigator assessment of acromegaly being adequately controlled. Patients were randomly assigned (3:2) to oral octreotide capsules or iSRL at the same dose and interval as before enrolment. Randomisation and drug dispensing were conducted through a qualified randomisation service provider (eg, interactive web or voice response system). The primary endpoint was a non-inferiority assessment (margin -20 percentage points) of proportion of participants maintaining biochemical response throughout the randomised treatment phase (IGF-I <1·3 × ULN using time-weighted average; assessed by comparing the lower bound of the 2-sided 95% CI for the difference in biochemical response between groups). IGF-I was assessed once a month during the run-in and randomised treatment phases (single sample). Efficacy and safety assessments were performed on the randomised population. This trial is registered with ClinicalTrials.gov, NCT02685709.
    Findings: Between Feb 11, 2016, and Aug 20, 2020, 218 patients were assessed for eligibility. 72 patients were excluded, and 146 participants were enrolled into the run-in phase. 116 patients completed the run-in phase and 30 participants discontinued treatment. 92 participants were randomly assigned to oral octreotide (n=55) or iSRL (n=37). 50 (91%) of 55 participants who received oral octreotide (95% CI 44-53) and 37 (100%) of 37 participants who received iSRLs (34-37) maintained biochemical response. The lower bound of the 2-sided 95% CI for the adjusted difference in proportions between the two treatment groups achieved the prespecified non-inferiority criterion of -20% (95% CI -19·9 to 0·5). 19 (35%) of 55 participants in the oral octreotide group and 15 (41%) of 37 participants in the iSRL group had treatment-related adverse events; the most common of which in both groups were gastrointestinal.
    Interpretation: Oral octreotide was non-inferior to iSRL treatment, and might be a favourable alternative to iSRLs for many patients with acromegaly.
    Funding: Chiasma.
    Translation: For the Russian translation of the abstract see Supplementary Materials section.
    Mesh-Begriff(e) Acromegaly/drug therapy ; Adult ; Capsules/therapeutic use ; Growth Hormone ; Human Growth Hormone/therapeutic use ; Humans ; Insulin-Like Growth Factor I/metabolism ; Insulin-Like Growth Factor I/therapeutic use ; Ligands ; Octreotide/adverse effects ; Octreotide/therapeutic use ; Receptors, Somatostatin/therapeutic use ; Treatment Outcome
    Chemische Substanzen Capsules ; Ligands ; Receptors, Somatostatin ; Human Growth Hormone (12629-01-5) ; Insulin-Like Growth Factor I (67763-96-6) ; Growth Hormone (9002-72-6) ; Octreotide (RWM8CCW8GP)
    Sprache Englisch
    Erscheinungsdatum 2021-12-22
    Erscheinungsland England
    Dokumenttyp Clinical Trial, Phase III ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ISSN 2213-8595
    ISSN (online) 2213-8595
    DOI 10.1016/S2213-8587(21)00296-5
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Zum Seitenanfang